1. Home
  2. LONA vs CYPH Comparison

LONA vs CYPH Comparison

Compare LONA & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LeonaBio Inc. Common Stock

LONA

LeonaBio Inc. Common Stock

N/A

Current Price

$7.50

Market Cap

81.5M

Sector

Health Care

ML Signal

N/A

CYPH

Cypherpunk Technologies Inc.

HOLD

Current Price

$0.69

Market Cap

73.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LONA
CYPH
Founded
2011
2011
Country
United States
United States
Employees
19
6
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.5M
73.4M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
LONA
CYPH
Price
$7.50
$0.69
Analyst Decision
Buy
Analyst Count
1
0
Target Price
$10.00
N/A
AVG Volume (30 Days)
29.4K
1.5M
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.21
$0.49
52 Week High
$14.21
$3.70

Technical Indicators

Market Signals
Indicator
LONA
CYPH
Relative Strength Index (RSI) 47.14 52.61
Support Level $6.86 $0.58
Resistance Level $9.78 $0.79
Average True Range (ATR) 0.47 0.05
MACD 0.03 0.01
Stochastic Oscillator 76.56 61.68

Price Performance

Historical Comparison
LONA
CYPH

About LONA LeonaBio Inc. Common Stock

LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.

About CYPH Cypherpunk Technologies Inc.

Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.

Share on Social Networks: